种植牙再生治疗相关药物性颌骨坏死范围综述
结果显示相关手术方案、植骨材料及成功率信息严重不足,与MRONJ相关的RT为上颌窦底提升,见于服用双膦酸盐和地舒单抗的患者。
要点
- 服用抗骨吸收药物患者种植规划时须谨慎评估MRONJ风险。
- 与MRONJ相关的再生治疗为上颌窦底提升。
- 植骨材料、手术方案及种植体参数等证据缺口明显。
核心结论
- 部分特定再生治疗合并其他因素可能带来MRONJ发生风险,但科学证据有限且存在诸多缺口。
- 需进一步研究以建立治疗高风险患者的循证临床指南。
研究设计与样本
- 范围综述,遵循PRISMA范围综述扩展版,由两名评价者独立检索MEDLINE-PubMed和Scopus。
主要发现
- 关于再生治疗的手术方案、植骨材料及成功与失败率的信息严重有限。
- 与MRONJ病例相关的再生治疗为服用双膦酸盐和地舒单抗患者的上颌窦底提升。
- 与再生治疗相关的种植治疗数据有限,如植入时间、种植体长度与直径及负载方案。
临床怎么用
- 对正在使用抗骨吸收药物的患者,种植治疗规划时应谨慎评估MRONJ发生风险。
- 不应低估再生治疗操作的不良结局,应向患者完整说明可能的风险。
局限性
- 科学证据有限,再生治疗相关MRONJ研究存在许多知识缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is limited scientific evidence regarding the medication-related osteonecrosis of the jaw (MRONJ) induced by regenerative therapy (RT) associated with dental implant treatment. Thus, the current scoping review systematically maps the MRONJ research induced by RTs in implant dentistry and recognizes the existing gaps in knowledge. DATA: Original studies and reviews investigating the impact of RT on the development of MRONJ were included. SOURCES: Two reviewers independently searched the MEDLINE-PubMed and Scopus databases according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) extension for Scoping Review and included articles published in English up to March 31, 2023. STUDY SELECTION: Eighteen articles that fulfilled the inclusion and exclusion criteria were included in this study. Ten mapping parameters for investigating the association of RTs with MRONJ development were examined and evaluated within the selected articles. RESULTS: There was severely limited information regarding the procedures of RTs including; the grafting materials, surgical protocols, and success and failure rates. The RT associated with MRONJ cases was sinus floor augmentation in patients taking bisphosphonate and denosumab. Moreover, there were limited data on the implant treatment associated with RTs such as time of insertion, implant length and diameter, and loading protocol. CONCLUSION: The current scoping review revealed that some specific RTs associated with other factors hold a potential risk of MRONJ occurrence. However, the scientific evidence is limited with many gaps. Further investigations are needed to establish an evidence-based clinical guideline for treating high-risk patients. CLINICAL SIGNIFICANCE: Clinicians should cautiously assess the risk of MRONJ development during implant treatment planning for patients undertaking antiresorptive medications. The adverse outcome of RT procedures should not be underestimated and a complete explanation of the possible risks should be given to the patients.
引用
- Al-Omari FA, Kuroshima S, Sawase T, et al. Medication-related Osteonecrosis of the Jaw Induced by Regenerative Therapy in Implant Dentistry: A Scoping Review. J Dent. 2023. PMID: 37708930. doi:10.1016/j.jdent.2023.104682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。